---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-26-000006"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:20:04.258995+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%

## Summary
- Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.
- Full-year GAAP diluted loss per share $4.45 includes $365.6M SNIA environmental charge.
- Full-year adjusted diluted EPS $3.90; adjusted free cash flow $183.3M.
- 2026 guidance: constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25.
- CMS increased reimbursement for VNS Therapy DRE procedures effective Jan 1, 2026; FDA approved cloud-based digital health platform.

## SEC filing metadata
- accession: 0001639691-26-000006
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000006/0001639691-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000006/livn-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-26-000006
- JSON: https://secwatch.observer/filing/0001639691-26-000006.json
- Plain text: https://secwatch.observer/filing/0001639691-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.